Heterocyclic THR-β receptor agonist compound and preparation method and use therefor

A compound shown in formula (I) or a stereoisomer thereof or a pharmaceutically acceptable salt thereof,

• wherein
• R1 and R2 are each independently selected from a halogen atom or a C1-6 alkyl group;
• R3 and R4 are each independently selected from hydrogen, a C1-6 alkyl group, an unsubstituted phenyl group, a phenyl group substituted with at least one substituent selected from a halogen atom, a trifluoromethyl group, a C1-6 alkyl group, a C1-6 alkoxyl group or a cyano group, an unsubstituted naphthyl group, a naphthyl group substituted with at least one substituent selected from a halogen atom, a trifluoromethyl group, a C1-6 alkyl group, a C1-6 alkoxyl group or a cyano group,
• or R3, R4, and adjacent
• jointly form the following six-membered ring
• wherein V is an unsubstituted five-to ten-membered aryl group, a five-to ten-membered aryl group substituted with at least one substituent selected from a halogen atom, a trifluoromethyl group, a C1-6 alkyl group, a C1-6 alkoxyl group or a cyano group, an unsubstituted five-to ten-membered heteroaryl group containing 1 or 2 heteroatoms selected from N, S and O, or a five-to ten-membered heteroaryl group that is substituted with at least one substituent selected from a halogen atom, a trifluoromethyl group, a
• C1-6 alkyl group, a C1-6 alkoxyl group or a cyano group and that contains one or two heteroatoms selected from N, S or O;
• R5 is selected from H or a C1-6 alkyl group;
• R6, R7, and R5 are each independently a C1-6 alkyl group;
• X is selected from —O— or —CH2—;
• Y is selected from —O— or —CH2—;
• Z and Z′ are each independently selected from —O— or —NH—;
• L is selected from —O—, —S— or —CH2—;
• and
• n is 1, 2 or 3;
• wherein the halogen atom is selected from F, Cl or Br.